Clinical oncology最新文献_第7页

Under-representation for Female Pelvis Cancers in Commercial Auto-segmentation Solutions and Open-source Imaging Datasets 商业自动分割解决方案和开源成像数据集中女性骨盆癌的代表性不足。

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.003

M. Thor , V. Williams , C. Hajj , L. Cervino , H. Veeraraghavan , S. Elguindi , N. Tyagi , A. Shukla-Dave , J.M. Moran

{"title":"Under-representation for Female Pelvis Cancers in Commercial Auto-segmentation Solutions and Open-source Imaging Datasets","authors":"M. Thor , V. Williams , C. Hajj , L. Cervino , H. Veeraraghavan , S. Elguindi , N. Tyagi , A. Shukla-Dave , J.M. Moran","doi":"10.1016/j.clon.2024.10.003","DOIUrl":"10.1016/j.clon.2024.10.003","url":null,"abstract":"<div><h3>Aim</h3><div>Artificial intelligence (AI) based auto-segmentation aids radiation therapy (RT) workflows and is being adopted in clinical environments facilitated by the increased availability of commercial solutions for organs at risk (OARs). In addition, open-source imaging datasets support training for new auto-segmentation algorithms. Here, we studied if the female and male anatomies are equally represented among these solutions.</div></div><div><h3>Materials and Methods</h3><div>Inquiries were sent to eight vendors regarding their clinically available OAR auto-segmentation solutions for each gender. The Cancer Imaging Archive (TCIA) was also screened for publicly available imaging datasets specific to the female and the male anatomy.</div></div><div><h3>Results</h3><div>All vendors provided AI based auto-segmentation solutions for the male pelvis and female breasts, while 5/8 vendors provided solutions for the female pelvis. The female breast and the female pelvis solutions were released at a median of 0.6 years and 2.3 years, respectively, after the release of the male pelvis solutions. Among 27 TCIA datasets identified, 15 involved the female anatomy (breast: 10; pelvis: 5) and 12 involved the male pelvis but no female-specific dataset included OAR segmentations, while three male pelvis datasets included OARs (ejaculatory duct, neurovascular bundle, penile bulb and verumontanum).</div></div><div><h3>Conclusion</h3><div>Commercial AI auto-segmentation solutions and open-source imaging datasets include considerably more solutions and OAR segmentations for male cancer over female cancer sites. This gender disparity is likely to propagate throughout the RT pipeline.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103651"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is exercise an important consideration in metastatic breast cancer? 运动是转移性乳腺癌患者的重要考虑因素吗？

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103718

A. Kuciejewska, C. Lai, M. Kitson, C. McDaid, M. Chody, N. Chopra

引用次数: 0

Filler advert SCIENCEDIRECT_210x280.Pdf 填充广告SCIENCEDIRECT_210x280.Pdf

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/S0936-6555(25)00035-4

引用次数: 0

Impact of anticoagulants on efficacy outcomes after initiation of Darolutamide in non- metastatic castrate resistant prostate cancer (nmCRPC) from the real world UK multi-centre RECORD study 来自英国真实世界多中心RECORD研究的抗凝剂对Darolutamide治疗非转移性去势抵抗性前列腺癌（nmCRPC）后疗效的影响

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.026

A. Stavropoulos , A. Bahl , P. White , L. Ashurst , M. Randhawa , A. Challapalli

引用次数: 0

Efficacy and safety of neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab in patients with HER2-positive early breast cancer - A retrospective study 新辅助多西他赛、卡铂、曲妥珠单抗、帕妥珠单抗治疗her2阳性早期乳腺癌的疗效和安全性——一项回顾性研究

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103717

L. Koudsi, C. Hockaday, N. Levitt, M. Tuthill, R. Roux, S. Lord, J. Chiramel

引用次数: 0

Neoadjuvant chemotherapy for early breast cancer in young patients: real-world outcomes 年轻早期乳腺癌患者的新辅助化疗：现实世界的结果

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103714

S.R. Javed, S. Mathur, K. DeSouza, A. Konstantis, D. Ottaviani, F. Raja, R. Roylance, T. Walsh, E. Papadimitraki

引用次数: 0

Alpelisib in advanced breast cancer – a real world report of toxicity and efficacy, a multi-centre analysis Alpelisib治疗晚期乳腺癌——一份真实世界的毒性和疗效报告，一项多中心分析

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103708

L. Morrison , D. Banon , I. Gill , N. Cunningham , A. Dua , A. Ballesteros , P.L. Marti , P. Galera , M. Alvarez-Maldonado , A. Iglesias , E. Carrillo , N.C. Turner , M. Parton , S. Johnston , E. Kipps , A.F.C. Okines

引用次数: 0

A retrospective audit of adherence to the IMPORT-HIGH recommendations on clip placement to facilitate breast boost radiotherapy 遵循IMPORT-HIGH建议放置夹子以促进乳房增强放疗的回顾性审计

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103710

L. Alizadeh, A. Mitchell, C. Kane, E. Halliday, S. Needleman

引用次数: 0

Single centre experience of neo-adjuvant chemotherapy for HER2 positive early breast cancer and impact of chemotherapy regimen on pathological complete response (pCR) HER2阳性早期乳腺癌新辅助化疗单中心经验及化疗方案对病理完全缓解（pCR）的影响

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103707

M. Joseph, A. Guppy, S. Sutherland, C. Westbury, W. Ng, D. Miles

引用次数: 0

National Oncology Trainee Collaborative for Healthcare Research (NOTCH)–Five Years On 全国肿瘤受训人员医疗保健研究合作组织（NOTCH）--五周年。